Adverse reactions attributed to entire drug class 'Immune checkpoint inhibitor (incl. programmed death receptor-1 (PD-1) inhibitor)' Please login to view adverse reactions.
Skin[22 reactions]
Bullous pemphigoid / pemphigoid
(2024): Li JH+, Zhongguo Yi Xue Ke Xue Yuan Xue Bao 46(6) , 872-882 (32 cases)(2022): Bur D+, J Am Acad Dermatol Aug , Online ahead of print (20 cases)(2022): Ingen-Housz-Oro S+, Melanoma Res Mar , Online ahead of print(2022): Schauer F+, Front Immunol Jul (e-Collection) (8 cases)(2021): Ogawa K+, Clin Drug Investig Jun , Online ahead of print [REVIEW](2020): Molina GE+, Br J Dermatol Jun , Online ahead of print (15 cases)(2020): Morris LM+, J Cutan Pathol Mar , Epub ahead of print (2 cases)(2019): Fontecilla NM+, J Drugs Dermatol 18(1) , 103 (1 case)(2019): Kosche C+, Dermatol Online J 25(10) (e-Collection) (1 case)(2019): Sadik CD+, Front Immunol 10 , 1934 (1 case)(2018): Lopez AT+, Int J Dermatol Apr , Epub ahead of print [REVIEW](2017): Bandino JP+, J Eur Acad Dermatol Venereol 31(8) , e378(2016): Jour G+, J Cutan Pathol 43(8) , 688 (5 cases)(2016): Naidoo J+, Cancer Immunol Res 4(5) , 383 (3 cases)Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))
(2025): Pacha O+, J Immunother Cancer 13(8) , e011401 (15 cases)(2023): L'Orphelin J-M+, J Eur Acad Dermatol Venereol Apr , Online ahead of print(2023): Martel J+, Hum Pathol May , Online ahead of print [REVIEW](2023): Medri M+, Ital J Dermatol Venerol 158(6) , 437-444(2022): Chen CH+, Curr Oncol 29(4) , 2871-2886 [REVIEW](2022): Juan-Carpena G+, Actas Dermosifiliogr 113(4) , 376-387 [REVIEW](2022): Salloum A+, Immunotherapy 14(6) , 489-503 [REVIEW]Cutaneous eruptions
Cutaneous toxicity / skin toxicity
(2022): Nikolaou V+, Br J Dermatol Jul , Online ahead of print(2022): Yamamoto T, Clin Cosmet Investig Dermatol 15 , 829-841 [REVIEW](2018): Sibaud V+, Ann Dermatol Venereol (French) Apr , Epub ahead of print [REVIEW](2018): Wang DY+, Cancer J 24(1) , 36 [REVIEW](2016): Spain L+, Cancer Treat Rev 44 , 51 [REVIEW]DRESS syndrome (Drug-induced hypersensitivity syndrome / DIHS)
Eczema / eczematous reaction / eczematous eruption
Granulomatous reaction
Keratoacanthoma (Grzybowski syndrome)
Lichen planus (includes hypertrophic lichen planus)
Lichen sclerosus
Lichenoid eruption / lichenoid reaction
Lipodystrophy / acquired generalized lipodystrophy
Lupus erythematosus (subacute cutaneous lupus erythematosus (SCLE))
Pruritus (itching)
Psoriasis
(2025): Papp KA+, J Eur Acad Dermatol Venereol Jul , Online ahead of print(2024): Pach JJ+, Dermatol Clin 42(3) , 481-493 [REVIEW](2023): Mebarki S+, Bull Cancer Mar , Online ahead of print2% (2021): Halle BR+, J Immunother Cancer 9(10) , e00306657% (exacerbation)(2016): Chia PL+, J Immunother 39(5) , 202 (flare)Rash
Raynaud's phenomenon
(2020): Khan S+, Oncologist Mar , Epub ahead of print (1 case) (with anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) therapy)Sarcoidosis / sarcoid-like reaction (cutaneous sarcoidosis)
Scleroderma
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN)
Vasculitis (angiitis) / cutaneous vasculitis (angiitis)
Vitiligo
(2025): Tang B+, Int J Cancer Sep , Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology) (2023): Lo J+, Arch Dermatol Res Feb , Online ahead of print (151 cases)(2021): Lommerts JE+, Expert Opin Drug Saf Apr , Online ahead of print [REVIEW](2019): Babai S+, Drug Saf Oct , Epub ahead of print [REVIEW](2017): Gauci ML+, Cancer Immunol Immunother 66(11) , 1399 [REVIEW](2016): Hwang SJ+, J Am Acad Dermatol 74(3) , 45515% Hair[2 reactions] Nails[1 reaction] Mucosal[3 reactions] Cardiovascular[8 reactions]
Capillary leak syndrome
Cardiotoxicity
(2025): Ogunniyi KE+, Cardiovasc Toxicol Jul , Online ahead of print [REVIEW](2024): Wang Y+, Front Cardiovasc Med Jun (e-Collection) (51 cases)(2024): Yamani N+, Cardiooncology 10(1) , 37 [REVIEW](2023): Ho CC+, J Chin Med Assoc 86(5) , 499-505(2023): Li X+, Front Immunol Feb (e-Collection) [REVIEW](2022): Ganesh S+, Front Cardiovasc Med Sep (e-Collection) [REVIEW](2022): Zito C+, Cancers (Basel) 14(21) , 5403 [REVIEW](2021): Arangalage D+, Cancer Treat Rev Aug , Online ahead of print [REVIEW](2021): Chen C+, Front Pharmacol Feb (e-Collection) [REVIEW](2021): Dolladille C+, Eur Heart J Sep , Online ahead of print [REVIEW](2018): Dong J+, Front Cardiovasc Med 5 , 9 [REVIEW]Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))
(2025): Cribari F+, Arch Cardiovasc Dis Jul , Online ahead of print54% (2024): Eldani C+, Front Oncol Jul (e-Collection) (grade 3–4)(2024): Nielsen DL+, JAMA Oncol Aug , Online ahead of print [REVIEW](2022): Wu S+, Front Cardiovasc Med Aug (e-Collection) [REVIEW](2021): Faron A+, Radiology Sep , Online ahead of print(2020): Khunger A+, Curr Oncol Rep 22(7) , 65 [REVIEW]Large-vessel vasculitis (includes giant cell arteritis)
Myocarditis
(2025): Müller-Jensen L+, J Immunother Cancer 13(9) , e011590 (pharmacogenomics) (2024): Tomsitz D+, Eur J Cancer Dec , Online ahead of print(2023): Coustal C+, J Immunother Cancer 11(5) , e004792 (29 cases)(2023): Gao J+, J Leukoc Biol May , Online ahead of print (multiomics)(2023): Moradi A+, Cureus 15(7) , e42071 [REVIEW](2022): Cadour F+, Radiology Mar , Online ahead of print (41 cases)(2022): Deharo F+, J Clin Med 11(19) , 5611 (3 cases)(2022): Longinow J+, Cancer Med Sep , Online ahead of print (11 cases) (with myasthenia gravis, myositis and myocarditis overlap syndrome)(2022): Thuny F+, JACC CardioOncol 4(5) , 624-628 [REVIEW](2022): Vasbinder A+, JACC CardioOncol 4(5) , 689-700 [REVIEW](2021): Esposito R+, Biomolecules 11(6) , 785 [REVIEW](2021): Matzen E+, Cardiooncology 7(1) , 27 (87 cases) [REVIEW](2021): Thuny F+, JACC CardioOncol 3(1) , 157-161 [REVIEW](2020): Balanescu DV+, Cardiovasc Pathol 47 , 107211 (3 cases)(2020): Cautela J+, J Immunother Cancer 8(2) , e001887 [REVIEW](2018): Mahmood SS+, J Am Coll Cardiol 71(16) , 1755 (35 cases)(2018): Tajiri K+, Jpn J Clin Oncol 48(1) , 7 [REVIEW](2017): Wang DY+, Curr Cardiol Rep 19(3) , 21 [REVIEW](2016): Johnson DB+, N Engl J Med 375(18) , 1749 (fatal / 2 cases)Myocarditis, myositis and myasthenia gravis overlap syndrome (Triple-M Syndrome / 3M Syndrome)
Takotsubo syndrome
Thromboembolism
Central Nervous System[11 reactions]
Bell's palsy (facial palsy)
(2023): Zhu J+, Int Immunopharmacol Nov , Online ahead of print (association)Cerebral pseudoprogression
Demyelination
Encephalitis
Fever (pyrexia) (includes hyperpyrexia)
Guillain-Barré syndrome / acute inflammatory demyelinating polyradiculoneuropathy / acute motor axonal neuropathy
Myelitis / myeloradiculitis
Neurological adverse effect / neurological deficit
(2024): Müller-Jensen L+, Data Brief Apr (e-Collection) (2022): Ruggiero R+, Front Oncol Mar (e-Collection) (2021): Cheng K+, Clin Med Insights Oncol Nov (e-Collection) [REVIEW](2021): Mikami T+, J Neurooncol 152(1) , 135-1447% [REVIEW](2021): Plaçais L+, Brain Commun 3(4) , fcab220 (40 cases)(2020): Haugh AM+, Expert Opin Drug Saf 19(4) , 479-488 [REVIEW](2020): Shi J+, Thorac Cancer 11(2) , 481-487 [REVIEW](2019): Möhn N+, J Clin Med 8(11) ~1% [REVIEW](2019): Pan PC+, Curr Oncol Rep 21(12) , 108 [REVIEW](2019): Sato K+, J Neurooncol 145(1) , 1-9 [REVIEW](2019): Shi J+, Zhongguo Fei Ai Za Zhi (Chinese) 22(10) , 633-638 [REVIEW]Neurological adverse effect / neurological deficit
Neurotoxicity
Paraneoplastic neurological syndromes
Endocrine/Metabolic[23 reactions]
Adrenal insufficiency (hypoadrenalism) / Addisonian crisis (includes Addison's disease)
Adrenalitis
Adrenocorticotropic hormone (corticotropin; ACTH) deficiency
Aspartate aminotransferase (AST) increased
Autoimmune Polyendocrine Syndrome Type 2
Diabetes insipidus
Diabetes mellitus (includes type 1 and type 2 diabetes mellitus)
(2025): Go SH+, Diabetes Metab J Jul , Online ahead of print (32 cases) (risk factors)(2025): Mitrache ML+, J Clin Med 14(18) , 6620 (3 cases) [REVIEW](2025): Zhan M+, Front Immunol Jan (e-Collection) (2024): Angelousi A+, Diseases 12(2) , 40 (4 cases) (with concomitant medication)(2024): Chen J+, Endocrine Jul , Online ahead of print [REVIEW](2024): Kani ER+, Endocrine Sep , Online ahead of print [REVIEW](2024): Ruiz-Esteves KN+, JAMA Oncol Aug , Online ahead of print(2023): Cho YK+, Diabetes Metab J Jul , Online ahead of print [REVIEW](2023): Liao D+, Int Immunopharmacol Jun , Online ahead of print [REVIEW](2023): Marsiglio J+, Front Immunol Aug (e-Collection) (18 cases) (+/- chemotherapy)(2022): Liu J+, Transl Oncol Jul , Online ahead of print (171 cases) [REVIEW](2021): Fischer M+, Harefuah (Hebrew) 160(10) , 657-662 (2 cases) [REVIEW](2021): Lo Preiato V+, Rev Endocr Metab Disord Jan , Online ahead of print [REVIEW](2021): Muniz TP+, Cancers (Basel) 14(1) , 89 (34 cases)(2021): Ogawa K+, Clin Drug Investig Jun , Online ahead of print [REVIEW](2020): Quandt Z+, Clin Exp Immunol 200(2) , 131-140 [REVIEW](2020): Zhang R+, Chin Med J (Engl) Aug , Online ahead of print [REVIEW](2020): Zheng Z+, Diabetes Metab Res Rev Jun , e3366 [REVIEW](2019): Kotwal A+, BMJ Open Diabetes Res Care 7(1) , e000591 [REVIEW]Diabetic ketoacidosis
Endocrine-related adverse effect / endocrinopathy
Graves' disease
Hyperglycemia (includes glucose increased)
(2022): Zhang W+, Front Endocrinol (Lausanne) Jan (e-Collection) (9 cases) [REVIEW] (hyperosmolar hyperglycemia)Hypertransaminasemia (hepatic transaminitis) / elevated transaminases
Hyponatremia
(2025): Tao C+, Front Immunol Jun (e-Collection) (association) (pharmacovigilance / pharmacoepidemiology) Hypoparathyroidism
Hypophysitis
(2024): van der Leij S+, Front Endocrinol (Lausanne) Jul (e-Collection) (67 cases)(2023): Chen P+, J Clin Med 12(10) , 3468 [REVIEW](2023): Esteves-Ferreira S+, J Cancer Res Clin Oncol Mar , Online ahead of print(2023): Quandt Z+, J Endocr Soc Feb (e-Collection) [REVIEW](2022): Jessel S+, Front Oncol Mar (e-Collection) (2020): du Payrat JA+, Bull Cancer (French) Mar , Epub ahead of print [REVIEW](2020): Khan S+, Oncologist Mar , Epub ahead of print (1 case) (with anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) therapy )(2020): Kurokawa R+, AJNR Am J Neuroradiol Aug , Online ahead of print(2019): Albarel F+, Eur J Endocrinol 181(3) , R107 [REVIEW](2019): Di Dalmazi G+, Expert Rev Endocrinol Metab 14(6) , 381 [REVIEW](2019): Thapi S+, J Immunother Cancer 7(1) , 248 (1 case)(2019): Wei KZ+, Melanoma Manag 6(1) , eCollection MMT1312% (2016): Spain L+, Cancer Treat Rev 44 , 51 [REVIEW]Hypopituitarism
Hypothyroidism
Metabolic syndrome (includes metabolic disorder)
(2025): Longo M+, Hormones (Athens) Oct , Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology) Pancreatic enzymes increased
Thyroid disorder
Thyroid dysfunction
(2025): Bai Y+, Endocrine Oct , Online ahead of print(2025): Shibutani Y+, J Immunother 48(5) , 183-188(2025): Wang A+, Endocrine Jan , Online ahead of print(2025): Yamauchi I+, Eur Thyroid J Jan , Online ahead of print [REVIEW](2024): Wang Y+, Heliyon 10(5) , e27077 [REVIEW](2023): Albarel F+, Ann Endocrinol (Paris) Mar , Online ahead of print [REVIEW](2022): Baek HS+, BMC Endocr Disord 22(1) , 8934% (2021): Zhou N+, Lung Cancer 161 , 34-41(2020): Pollack R+, J Clin Endocrinol Metab Jul , Online ahead of print39% (2020): Zhou Y+, Int Immunopharmacol Dec , Online ahead of print(2018): De Bruyne P+, Arch Dis Child 103(1) , 78 (long-term use)(2017): Chalan P+, J Endocrinol Invest Dec , Epub ahead of print [REVIEW](2016): Spain L+, Cancer Treat Rev 44 , 51 [REVIEW]Thyroiditis
Thyrotoxicosis
Gastrointestinal/Hepatic[24 reactions]
Abdominal pain
Celiac disease / coeliac disease
Cholangitis / sclerosing cholangitis
(2021): Pi B+, Eur J Gastroenterol Hepatol Sep , Online ahead of print [REVIEW](2020): Fujii M+, Clin J Gastroenterol Sep , Online ahead of print (1 case / male) (with chemotherapy)Cholestasis / cholestatic jaundice
(2025): Yan X+, Int J Surg Jun , Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology) Colitis
(2025): Kim TK+, Korean J Intern Med 40(1) , 49-564% (2025): Meng K+, Front Immunol Oct (e-Collection) (57 cases) (risk factors)(2025): Pesch G+, Cancer Immunol Res Apr , Online ahead of print (pharmacogenomics) (2025): Van Holder B+, J Clin Med 14(20) , 7219 (77 cases)(2025): Zaher A+, Expert Opin Drug Saf Apr , Online ahead of print [REVIEW](2024): Lenti MV+, ESMO Open Jul , Online ahead of print (96 cases)(2024): Zoghbi M+, Support Care Cancer 32(10) , 680 [REVIEW](2023): Desmedt V+, Eur J Cancer 187 , 36-57 [REVIEW](2023): Losurdo G+, Biomedicines 11(5) , 1496 [REVIEW](2023): Mebarki S+, Bull Cancer Mar , Online ahead of print5% (2023): Nakane T+, Kurume Med J Apr , Online ahead of print [REVIEW](2023): Terrin M+, Int J Mol Sci 24(14) , 11504 [REVIEW](2022): Vaziri H+, J Clin Gastroenterol Apr , Online ahead of print [REVIEW](2021): Farha N+, Clin Res Hepatol Gastroenterol Jul , Online ahead of print4% (2021): Ogawa K+, Clin Drug Investig Jun , Online ahead of print [REVIEW](2021): Portenkirchner C+, Pharmaceuticals (Basel) 14(4) , 367 [REVIEW](2021): Yanai S+, Digestion Sep , Online ahead of print [REVIEW](2020): Bellaguarda E+, Am J Gastroenterol Jan , Epub ahead of print [REVIEW](2019): Abu-Sbeih H+, Curr Opin Gastroenterol Oct , Epub ahead of print [REVIEW](2019): Chen C+, Oncoimmunology 8(5) , e1581547 (≥ grade 3)(2019): Delasos L+, Case Rep Oncol Med Jul , 2019:9069354 (1 case)(2019): Som A+, World J Clin Cases 7(4) , 405 [REVIEW](2019): Yanai S+, Dig Endosc Oct , Epub ahead of print (7 cases) [REVIEW](2017): Collins M+, Ann Oncol 28(11) , 2860(2016): Spain L+, Cancer Treat Rev 44 , 51 [REVIEW]Diarrhea
(2024): Zoghbi M+, Support Care Cancer 32(10) , 680 [REVIEW](2019): Abu-Sbeih H+, Curr Opin Gastroenterol Oct , Epub ahead of print [REVIEW](2019): Yanai S+, Dig Endosc Oct , Epub ahead of print (11 cases) [REVIEW](2017): Collins M+, Ann Oncol 28(11) , 2860(2017): Gauci ML+, Cancer Immunol Immunother 66(11) , 1399 [REVIEW](2016): Spain L+, Cancer Treat Rev 44 , 51 [REVIEW]Enterocolitis
Enteropathy
Gastritis / pangastritis / gastric irritation
Gastrointestinal adverse reaction
Gastrointestinal bleeding
Gastrointestinal disorder / discomfort
Gastrointestinal perforation / perforated colon / gastric perforation
Hepatic (liver) disorder / hepatobiliary disorder / hepatic (liver) dysfunction
(2025): Oh J+, Medicine (Baltimore) 104(40) , e44700 (hepatic autoimmune disorders) (pharmacovigilance / pharmacoepidemiology) (2023): Yamada T+, Int J Clin Pharm Jan , Online ahead of print (with acetaminophen)Hepatitis
(2022): Farshidpour M+, Middle East J Dig Dis 14(2) , 244-253 [REVIEW](2022): Liu Z+, Front Pharmacol Jan (e-Collection) [REVIEW](2022): Miah A+, J Cancer Res Clin Oncol Sep , Online ahead of print6% (2021): Biewenga M+, Hepatol Int Feb , Online ahead of print2% (grade 3–4)(2020): Gauci ML+, Clin Res Hepatol Gastroenterol Aug , Online ahead of print6% (≥ grade 3)(2019): Chen C+, Oncoimmunology 8(5) , e1581547 (≥ grade 3)(2017): Gauci ML+, Cancer Immunol Immunother 66(11) , 1399 [REVIEW](2016): Spain L+, Cancer Treat Rev 44 , 51 [REVIEW]Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)
(2025): Cao R+, Front Oncol Oct (e-Collection) (severe / 32 cases)(2025): Yamamoto T+, Hepatol Res May , Online ahead of print (≥ grade 3 / 80 cases)(2024): Ito T+, Hepatol Res Jun , Online ahead of print [REVIEW](2024): Jiang Y+, Curr Oncol 31(11) , 7129-714314% (7% ≥ grade 3)(2024): Kawano M+, Diagnostics (Basel) 14(8) , 815(2024): Yue M+, Int Immunopharmacol Mar , Online ahead of print [REVIEW](2023): Atallah E+, JHEP Rep Oct (e-Collection) 9% (associated with combination therapy)(2023): Gudd CLC+, Semin Liver Dis 43(4) , 402-417 [REVIEW](2023): Hountondji L+, JHEP Rep Jun (e-Collection) (117 cases)(2023): Kobayashi T+, J Clin Transl Hepatol 11(5) , 1239-1245 [REVIEW](2022): Taherian M+, J Clin Transl Pathol 2(3) , 83-90 [REVIEW](2021): Ito T+, Hepatol Int Aug , Online ahead of print5% (≥ grade 3)(2020): Yamamoto A+, J Cancer Res Clin Oncol Nov , Online ahead of print(2017): Cramer P+, Curr Gastroenterol Rep 19(1) , 3 [REVIEW]Liver dysfunction
Liver injury
Nausea
Pancreatic injury
Pancreatitis / acute pancreatitis
Pneumatosis intestinalis / pneumatosis cystoides intestinalis
Sclerosing cholangitis
Vomiting
Genitourinary[2 reactions] Hematologic[11 reactions] Neuromuscular/Skeletal[10 reactions]
Arthralgia
Arthritis / polyarthritis
Asthenia / fatigue
Inflammatory arthritis
(2025): Fisher BA+, Clin Med (Lond) Aug , Online ahead of print [REVIEW](2025): Georgios I+, Autoimmun Rev Oct , Online ahead of print [REVIEW](2025): Yoon JS+, Intern Med J Jan , Online ahead of print (20 cases)(2024): Ghosh N+, Rheum Dis Clin North Am 50(2) , 325-335 [REVIEW](2024): Gómez-Puerta JA+, Rheum Dis Clin North Am 50(2) , 161-179 [REVIEW](2024): Rose N+, Eur J Rheumatol Jan , Online ahead of print [REVIEW](2024): Singh N+, Rheum Dis Clin North Am 50(2) , 269-279 [REVIEW](2022): Chan KK+, J Inflamm Res May (e-Collection) [REVIEW](2022): Gómez-Puerta JA+, Front Med (Lausanne) Jun (e-Collection) (2022): Ghosh N+, Semin Arthritis Rheum Oct , Online ahead of print(2022): Jensen AK+, Biomed Pharmacother Feb , Online ahead of print [REVIEW](2022): Kim ST+, Nat Commun 13(1) , 1970 (20 cases)(2020): Angelopoulou F+, Rheumatol Int Aug , Online ahead of print58% [REVIEW](2019): Braaten TJ+, Ann Rheum Dis Sep , Epub ahead of printMusculoskeletal adverse effects
(2023): Liu H+, Front Pharmacol Oct (e-Collection) (FDA Adverse Event Reporting System data)Myalgia/Myositis/Myopathy/Myotoxicity
Myasthenia gravis
(2023): Masi G+, Ann Clin Transl Neurol Mar , Online ahead of print (5 cases)(2022): Longinow J+, Cancer Med Sep , Online ahead of print (11 cases) (with myasthenia gravis, myositis and myocarditis overlap syndrome)(2022): Marco C+, J Clin Med 12(1) , 130 (6 cases)(2022): Niimura T+, J Clin Pharmacol Dec , Online ahead of print (age association)(2021): Ogawa K+, Clin Drug Investig Jun , Online ahead of print [REVIEW](2021): Pathak R+, Oncologist Aug , Online ahead of print [REVIEW](2020): Huang YT+, Front Neurol 11 , 634 [REVIEW] (immune-related)(2020): Yao S+, Zhongguo Fei Ai Za Zhi (Chinese) Aug , Online ahead of print [REVIEW](2019): Becquart O+, J Immunother Jun , Epub ahead of print [REVIEW](2019): Lara MS+, Clin Lung Cancer Apr , Epub ahead of print (1 case)Myofasciitis
Polymyalgia rheumatica
Psoriatic arthralgia / psoriatic arthritis
Ocular[5 reactions] Otic[2 reactions] Renal[5 reactions]
Fanconi syndrome (proximal tubular dysfunction)
Nephritis / interstitial nephritis / tubulointerstitial nephritis
Nephropathy
Nephrotic syndrome
(2025): Ye J+, Ren Fail Dec , Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology) Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury
(2025): Ding Z+, Am J Cancer Res 15(4) , 1480-1493 [REVIEW](2024): Thomas AS+, Gastro Hep Adv 3(3) , 361-367 (229 cases)(2023): Seethapathy H+, Immunol Rev Jul , Online ahead of print [REVIEW](2022): Catalano M+, Front Med (Lausanne) Dec (e-Collection) [REVIEW](2022): Gérard AO+, Clin Kidney J 15(10) , 1881-1887 (suggested association with administration of fluindione, a non-steroidal anti-inflammatory drug, or a proton-pump inhibitor)(2022): Lv D+, Discov Med 33(170) , 137-141 [REVIEW](2022): Tian R+, Kidney Dis (Basel) 8(3) , 190-201 [REVIEW](2022): Verploegen MFA+, Kidney360 3(3) , 524-529 (16 cases)(2020): Tinawi M+, Cureus 12(12) , e12204 [REVIEW]Respiratory[7 reactions]
Interstitial lung disease / interstitial pneumonitis / interstitial pneumonia (cryptogenic organizing pneumonia) / drug-induced interstitial lung disease
(2025): Kanaji N+, J Pers Med 15(3) , 11518% (fatal / 6 cases)(2025): Nakai S+, Respir Investig 63(3) , 259-26410% (2024): Utsunomiya A+, Expert Opin Drug Saf Dec , Online ahead of print(2024): Yokoi M+, J Pharm Health Care Sci 10(1) , 526% (2022): Camard M+, Respir Med Res Nov , Online ahead of print(2019): Nakanishi Y+, Respir Investig Jun , Epub ahead of print17% (pre-existing lung abnormalities a risk factor)Pneumonia
Pneumonitis
(2025): Casal A+, Expert Rev Respir Med Jul , Online ahead of print1–7% [REVIEW](2024): Matsukane R+, J Immunother Cancer 12(12) , e01011410–20% (2023): Allen E+, Front Oncol Oct (e-Collection) (10 cases) (association with patients with pre-existing obstructive pulmonary disease)(2022): Yin J+, Front Immunol Apr (e-Collection) 3–5% [REVIEW] (non-small-cell lung cancer patients)(2021): Abraham G+, Int J Cancer Nov , Online ahead of print4% (2021): Naganuma K+, Chemotherapy Apr , Online ahead of print (grade 3 / 1 case)(2021): Sun Z+, Invest New Drugs Jan , Online ahead of print (19 cases)(2020): Sakamoto K+, Respir Investig Jul , Online ahead of print [REVIEW](2020): Tian S+, Int J Radiat Oncol Biol Phys Jan , Epub ahead of print11% (grade 3)(2020): Tian Z+, Cancer Manag Res 12 , 133910% (with doxorubicin)(2020): Zhu S+, Front Oncol 10 , 17853% [REVIEW](2019): Chen C+, Oncoimmunology 8(5) , e1581547 (≥ grade 3)(2019): Zhou H+, Front Pharmacol 10 , e3874% (≥ grade 3)(2017): Delaunay M+, Eur Respir J 50(2) , Epub16% (2017): Gauci ML+, Cancer Immunol Immunother 66(11) , 1399 [REVIEW](2017): Khunger M+, Chest 152(2) , 271 [REVIEW](2017): Zhang S+, Mol Cancer Ther 16(8) , 1588 [REVIEW](2016): Nishino M+, JAMA Oncol 2(12) , 1607 [REVIEW](2016): Tabchi S+, Curr Opin Oncol 28(4) , 269 [REVIEW]Pulmonary toxicity
Respiratory disorder
Sinonasal disease
Sinusitis (see also rhinitis / rhinosinusitis)
Other[4 reactions]
Adverse effects / adverse reactions
(2025): Alwhaibi A+, J Clin Med 14(2) , 388(2024): Miller S+, Lancet Oncol Nov , Online ahead of print(2024): Tan K+, Clin Transl Oncol Jun , Online ahead of print [REVIEW](2024): Tyagi S+, Crit Rev Oncol Hematol May , Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology) (2023): Elmakaty I+, Cancer Cell Int 23(1) , 90 [REVIEW](2023): Liao D+, Int Immunopharmacol Feb , Online ahead of print (with epidermal growth factor receptor (EGFR) / anaplastic lymphoma kinase (ALK) inhibitor)(2022): Wen Y+, Expert Rev Hematol Aug , Online ahead of print [REVIEW](2022): Xu J+, Front Immunol Jan (e-Collection) [REVIEW] (with chemotherapy)(2021): Al Nuhait M+, Sci Prog 104(1) (e-Collection) [REVIEW](2021): Paderi A+, Curr Oncol 28(5) , 3259-3267 [REVIEW](2021): Pala L+, Expert Opin Drug Saf Sep , Online ahead of print [REVIEW](2021): Perdigoto AL+, Curr Opin Immunol 69 , 29-38 [REVIEW](2021): Qi Y+, Front Pharmacol Jun (e-Collection) 64% (13% severe)(2021): Tian Y+, Front Oncol May (e-Collection) [REVIEW](2020): Allouchery M+, J Immunother Cancer 8(2) , e001622(2020): Cutroneo PM+, Br J Clin Pharmacol Jun , Online ahead of print49% (serious) [REVIEW](2020): Hommes JW+, Front Oncol Feb (e-Collection) [REVIEW](2020): Wang BC+, Oral Oncol Mar , Epub ahead of print94% (20% ≥ grade 3)(2020): Yamaguchi O+, Cancer Chemother Pharmacol Mar , Epub ahead of print(2019): Bjornhart B+, Acta Oncol May , Epub ahead of print24% (grade 3–5)(2019): Fox B+, Clin Transl Oncol Jun , Epub ahead of print [REVIEW](2019): Huang YF+, Front Oncol Oct (e-Collection) [REVIEW] (with chemotherapy)(2019): Ni X+, Clin Res Hepatol Gastroenterol Jun , Epub ahead of print12% ≥ grade 3 [REVIEW](2019): Zhou H+, Front Pharmacol 10 , e38774% (24% ≥ grade 3; fatal / 2 cases)(2017): Hu YB+, Transl Lung Cancer Res 6(Suppl 1) , S8 [REVIEW](2017): Le Burel S+, Eur J Cancer 82 , 34Death
(2025): Kanaji N+, J Pers Med 15(3) , 115 (6 cases)(2023): Guo Q+, Front Pharmacol Jan (e-Collection) (7 cases ) [REVIEW] (case study analysis)(2022): Jing X+, Immunotherapy Sep , Online ahead of print (4 cases)(2019): Zhou H+, Front Pharmacol 10 , e387 (2 cases) [REVIEW](2018): Wang DY+, JAMA Oncol 4(12) , 1721-1728 [REVIEW](2016): Johnson DB+, N Engl J Med 375(18) , 1749 (2 cases)Generalized edema (includes anasarca)
Immune-related adverse effect
(2025): Le J+, Hum Vaccin Immunother Feb (e-Collection) [REVIEW](2025): Mizuno K+, Oncologist 30(6) , oyaf12018% (severe)(2025): Sun Y+, Curr Opin Immunol Apr , Online ahead of print [REVIEW](2024): Guo AJ+, World J Clin Oncol 15(8) , 1002-1020 [REVIEW](2024): Jayathilaka B+, Br J Cancer Nov , Online ahead of print [REVIEW](2024): Jayathilaka B+, Br J Cancer Dec , Online ahead of print (Correction)(2024): Jayathilaka B+, Crit Rev Oncol Hematol Dec , Online ahead of print [REVIEW](2024): Pozzessere C+, Cancers (Basel) 16(14) , 2585 [REVIEW](2024): Riveiro-Barciela M+, Gastroenterol Hepatol Jan , Online ahead of print [REVIEW](2023): Burnett DL+, Front Endocrinol (Lausanne) Oct (e-Collection) [REVIEW](2023): Geng R+, Front Immunol Mar (e-Collection) (2023): Guérin C+, Bull Cancer May , Online ahead of print31% (≥ grade 2)(2023): Lou S+, Front Pharmacol Apr (e-Collection) 39% (2023): Velev M+, Eur J Cancer 179 , 28-47(2022): Jing X+, Immunotherapy Sep , Online ahead of print (fatal / 4 cases)(2022): Storm BN+, J Geriatr Oncol Jun , Online ahead of print(2021): Abdayem P+, Expert Opin Drug Saf Jan , Online ahead of print [REVIEW](2021): Husain B+, J Cancer Res Clin Oncol Apr , Online ahead of print(2021): Qi Y+, Front Pharmacol Jun (e-Collection) 15% (2021): Zhao Q+, Front Immunol Sep (e-Collection) [REVIEW](2021): Zhao Z+, Target Oncol May , Online ahead of print9% (? grade 3)(2020): Abou Alaiwi S+, J Immunother Cancer 8(1) , e00014445% (2020): Allenbach Y+, Autoimmun Rev Jun , Online ahead of print [REVIEW] (rheumatic and musculoskeletal Immune-related adverse effects)(2020): Karimian Z+, BMC Cancer 20(1) , 1128 [REVIEW](2020): Qin Q+, Zhongguo Fei Ai Za Zhi (Chinese) Aug , Online ahead of print [REVIEW](2020): Tang H+, Zhongguo Yi Xue Ke Xue Yuan Xue Bao (Chinese) 42(6) , 825-830 [REVIEW] (biomarkers)(2020): Triggianese P+, Autoimmun Rev Jun , 102590 [REVIEW](2019): Rambhia PH+, Int J Clin Oncol Jul , Epub ahead of print [REVIEW] (sarcoidosis-like granulomas)(2019): Tison A+, Arthritis Rheumatol Aug , Epub ahead of print(2019): Wei KZ+, Melanoma Manag 6(1) , eCollection MMT1329% 
